Guidewire Software vs DXC Technology: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Guidewire Software Inc (GWRE)

Q3 202615 Aug – 4 Sep 2026

▲2▼1

Guidewire's strong ARR and cloud growth overshadowed by soft guidance

Qusar AI Agent Framework launch Guidewire launched Qusar, an AI agent framework for insurers to build and deploy AI across policy, claims, and billing. This deepens its cloud platform and could drive more adoption, but also adds execution risk if insurers are slow to use it.
New product launch that could boost future revenue and lock in customers.
Strong FY2027 ARR guidance and Nationwide deal Guidewire guided FY2027 ARR to $1.45–$1.46B with 84% cloud mix, after FY2026 ARR rose 19% to $1.242B. It also signed a long-term cloud migration deal with Nationwide. This shows solid demand and a growing recurring revenue base.
Key financial targets and a major customer win that underpin the bull case.
Cautious Q3 guidance triggers sharp sell-off Despite beating Q2 estimates, Guidewire guided Q3 revenue to $375M, below the $387.6M consensus, citing lumpy deal timing and normalized retention. The stock fell as much as 21% intraday, reflecting fears that growth may slow.
The main reason for the recent price drop and a key risk to the growth story.

August 202615 Aug – 4 Sep 2026

▲2▼1

Guidewire's strong ARR and cloud growth overshadowed by soft guidance

Qusar AI Agent Framework launch Guidewire launched Qusar, an AI agent framework for insurers to build and deploy AI across policy, claims, and billing. This deepens its cloud platform and could drive more adoption, but also adds execution risk if insurers are slow to use it.
New product launch that could boost future revenue and lock in customers.
Strong FY2027 ARR guidance and Nationwide deal Guidewire guided FY2027 ARR to $1.45–$1.46B with 84% cloud mix, after FY2026 ARR rose 19% to $1.242B. It also signed a long-term cloud migration deal with Nationwide. This shows solid demand and a growing recurring revenue base.
Key financial targets and a major customer win that underpin the bull case.
Cautious Q3 guidance triggers sharp sell-off Despite beating Q2 estimates, Guidewire guided Q3 revenue to $375M, below the $387.6M consensus, citing lumpy deal timing and normalized retention. The stock fell as much as 21% intraday, reflecting fears that growth may slow.
The main reason for the recent price drop and a key risk to the growth story.

Latest15 Aug – 4 Sep 2026

▲2▼1

Guidewire's strong ARR and cloud growth overshadowed by soft guidance

Qusar AI Agent Framework launch Guidewire launched Qusar, an AI agent framework for insurers to build and deploy AI across policy, claims, and billing. This deepens its cloud platform and could drive more adoption, but also adds execution risk if insurers are slow to use it.
New product launch that could boost future revenue and lock in customers.
Strong FY2027 ARR guidance and Nationwide deal Guidewire guided FY2027 ARR to $1.45–$1.46B with 84% cloud mix, after FY2026 ARR rose 19% to $1.242B. It also signed a long-term cloud migration deal with Nationwide. This shows solid demand and a growing recurring revenue base.
Key financial targets and a major customer win that underpin the bull case.
Cautious Q3 guidance triggers sharp sell-off Despite beating Q2 estimates, Guidewire guided Q3 revenue to $375M, below the $387.6M consensus, citing lumpy deal timing and normalized retention. The stock fell as much as 21% intraday, reflecting fears that growth may slow.
The main reason for the recent price drop and a key risk to the growth story.

DXC Technology Co (DXC)

Q3 202623 Jun – 30 Jul 2026

▲2▼2

DXC's Weak Earnings and Legal Probe Weigh on Shares

Securities Fraud Investigation Pomerantz LLP is investigating DXC for possible securities fraud tied to its May 7 earnings miss, which already caused a 21% stock drop. The probe adds legal uncertainty and could lead to fines or lawsuits, making investors more cautious and pressuring the stock.
This is a new legal risk that directly threatens DXC's finances and reputation, explaining recent price weakness.
Wins $213.56 Million in Trade Secrets Case DXC collected $213.56 million from Tata Consultancy Services after the Supreme Court upheld a trade secrets ruling. This cash boost strengthens DXC's balance sheet and shows it will defend its intellectual property, a positive for investors.
This is a new, concrete financial gain that improves DXC's cash position and could support future investments.
Launches Private Cloud+ for Regulated Industries DXC launched Private Cloud+, a hybrid cloud solution for sensitive workloads in finance, healthcare, and government. This expands its product lineup and targets high-value clients, potentially boosting future revenue and showing innovation.
This is a new product that could drive demand and revenue growth, a positive strategic move.
IBM Warning and Weak Q2 Earnings IBM's revenue warning signaled stalled enterprise deals, dragging DXC shares down 4.2%. Then DXC's Q2 adjusted EPS missed estimates by 11.3% and next-quarter revenue guidance was below expectations, sending shares down another 5.2%. These reinforce concerns about weak demand and execution.
These are new negative developments that directly impact DXC's earnings and investor confidence, explaining recent price declines.

July 202623 Jun – 30 Jul 2026

▲2▼2

DXC's Weak Earnings and Legal Probe Weigh on Shares

Securities Fraud Investigation Pomerantz LLP is investigating DXC for possible securities fraud tied to its May 7 earnings miss, which already caused a 21% stock drop. The probe adds legal uncertainty and could lead to fines or lawsuits, making investors more cautious and pressuring the stock.
This is a new legal risk that directly threatens DXC's finances and reputation, explaining recent price weakness.
Wins $213.56 Million in Trade Secrets Case DXC collected $213.56 million from Tata Consultancy Services after the Supreme Court upheld a trade secrets ruling. This cash boost strengthens DXC's balance sheet and shows it will defend its intellectual property, a positive for investors.
This is a new, concrete financial gain that improves DXC's cash position and could support future investments.
Launches Private Cloud+ for Regulated Industries DXC launched Private Cloud+, a hybrid cloud solution for sensitive workloads in finance, healthcare, and government. This expands its product lineup and targets high-value clients, potentially boosting future revenue and showing innovation.
This is a new product that could drive demand and revenue growth, a positive strategic move.
IBM Warning and Weak Q2 Earnings IBM's revenue warning signaled stalled enterprise deals, dragging DXC shares down 4.2%. Then DXC's Q2 adjusted EPS missed estimates by 11.3% and next-quarter revenue guidance was below expectations, sending shares down another 5.2%. These reinforce concerns about weak demand and execution.
These are new negative developments that directly impact DXC's earnings and investor confidence, explaining recent price declines.

Latest23 Jun – 30 Jul 2026

▲2▼2

DXC's Weak Earnings and Legal Probe Weigh on Shares

Securities Fraud Investigation Pomerantz LLP is investigating DXC for possible securities fraud tied to its May 7 earnings miss, which already caused a 21% stock drop. The probe adds legal uncertainty and could lead to fines or lawsuits, making investors more cautious and pressuring the stock.
This is a new legal risk that directly threatens DXC's finances and reputation, explaining recent price weakness.
Wins $213.56 Million in Trade Secrets Case DXC collected $213.56 million from Tata Consultancy Services after the Supreme Court upheld a trade secrets ruling. This cash boost strengthens DXC's balance sheet and shows it will defend its intellectual property, a positive for investors.
This is a new, concrete financial gain that improves DXC's cash position and could support future investments.
Launches Private Cloud+ for Regulated Industries DXC launched Private Cloud+, a hybrid cloud solution for sensitive workloads in finance, healthcare, and government. This expands its product lineup and targets high-value clients, potentially boosting future revenue and showing innovation.
This is a new product that could drive demand and revenue growth, a positive strategic move.
IBM Warning and Weak Q2 Earnings IBM's revenue warning signaled stalled enterprise deals, dragging DXC shares down 4.2%. Then DXC's Q2 adjusted EPS missed estimates by 11.3% and next-quarter revenue guidance was below expectations, sending shares down another 5.2%. These reinforce concerns about weak demand and execution.
These are new negative developments that directly impact DXC's earnings and investor confidence, explaining recent price declines.